Our Science
We leverage deep scientific insights to engineer therapies that matter. Our goal is to transform ”undruggable” targets into life-saving realities.
Scroll to explore
Development Pipeline
Strategic asset diversification across oncology and immunology. Our lead assets are progressing towards late-stage registration trials.
UA007
SECRETED PROTEIN
Acute Gout / Immunity
PROTEIN
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
UA021
SELECTIVE INHIBITOR
Various Autoimmune Diseases
SMALLMOLECULE
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
UA026
INFLAMMATION TARGET
Various Autoimmune Diseases
SMALLMOLECULE
Preclinical
IND-Enabling
Ph1
Ph2
Ph3
UA022/AZD0022
KRAS G12D
Advanced Solid Tumor
SMALLMOLECULE
Preclinical
IND-Enabling
Ph1
Ph2
Ph3